Writer reviews the pathophysiology of obesity such as the purpose of incretin hormones and also the system of motion, efficacy, and safety of GLP-one receptor agonists as antiobesity medications. Dr. Camilleri and co-authors Observe they have been in agreement with many of the endorsed statem